The genus Thalictrum belongs to the buttercup family, Ranunculaceae, and its members have long histories in traditional medicine. Across African and Asian healing systems, preparations from these herbs have been used to treat fevers, infections, gastrointestinal complaints, wounds, and inflammation. Yet, as the review authors emphasize, historical use is not the same as validated efficacy. To move beyond anecdote, the team systematically mined PubMed, ScienceDirect, Scopus, Google Scholar, and ethnobotanical surveys, ultimately identifying eleven Thalictrum species native to Africa and Asia with documented medicinal relevance.

Those eleven species, ranging from Thalictrum rhynchocarpum of East Africa to Himalayan and East Asian species such as T. foliolosum, T. cultratum, and T. delavayi, share a common chemical signature. Phytochemical analyses reveal abundant isoquinoline alkaloids, the same structural family that gave the world berberine and related compounds, alongside flavonoids, terpenoids, tannins, and diverse phenolics. In species such as T. cultratum, chemists have isolated dozens of bisbenzylisoquinoline and aporphine alkaloids, some with demonstrable antiproliferative effects against tumor cells in laboratory settings. From T. alpinum, researchers previously reported northalrugosidine, a bisbenzyltetrahydroisoquinoline alkaloid with in vivo antileishmanial activity.

The pharmacological signals extend across several therapeutic domains. Preliminary studies point to antimicrobial, antioxidant, anti-inflammatory, anticancer, and antidiabetic effects. Work on T. foliolosum from the northwestern Himalayas has documented antifungal activity, hepatoprotective effects, anti-urolithiatic potential against kidney stones, and antimalarial activity in mouse models of lethal malaria. Extracts of T. minus have shown protective effects against chemically induced acute lung injury in mice, while T. baicalense has yielded alkaloid dimers with antitumor activity and isoflavones and lignans with anti-inflammatory properties. Studies of T. rhynchocarpum root extract demonstrated antidiarrhoeal effects in mice.

Here, however, the review delivers its most sobering finding. When the authors applied structured quality criteria to the existing literature, they found that approximately 70 percent of studies lacked adequate experimental controls. Only four of the eleven species have had their principal bioactive compounds quantified. Most strikingly, eight of the eleven species have never been tested in any in vivo model, meaning that the vast majority of therapeutic claims rest entirely on test tube experiments with crude extracts of unknown composition. Toxicity data, an absolute prerequisite for any clinical translation, exist for only two species.

This pattern matters because crude extract pharmacology is notoriously vulnerable to false positives. Without proper controls, effects attributed to plant chemicals can arise from solvent artifacts, tannin nonspecificity, or assay interference. Without quantification, doses cannot be standardized between experiments, making results irreproducible. And without in vivo validation, no claim of therapeutic relevance can survive contact with physiological reality, where absorption, metabolism, distribution, and toxicity conspire to eliminate most candidate molecules before they ever reach a clinic.

To their credit, the review authors do not simply catalogue the deficits. They propose a strategic framework for converting this botanical bounty into genuine drug candidates. The framework calls for bioassay-guided isolation, in which fractionation is paired with iterative activity testing to identify the specific molecules responsible for observed effects. It then demands rigorous in vivo validation, mechanistic studies to explain how active compounds work at the molecular level, and attention to sustainable sourcing so that promising species are not driven toward extinction by harvest pressure before their value is established.

The framework aligns with broader trends in ethnopharmacology, where traditional knowledge increasingly serves as a map for modern chemistry rather than as evidence in its own right. The World Health Organization has documented the growing global integration of traditional and modern medicine, and the review situates Thalictrum within this context, noting that species in the genus appear in Tibetan, Ayurvedic, Chinese, and various African medical traditions. The chemotaxonomic richness of the genus, particularly its isoquinoline alkaloid diversity, makes it a natural candidate for systematic drug discovery campaigns using modern metabolomic techniques such as UHPLC-QTOF profiling.

For drug discovery pipelines, the Thalictrum findings carry both encouragement and caution. The encouragement lies in the sheer chemical novelty on display; new alkaloid skeletons continue to emerge from these plants, including novel benzo[c]azepinones and dimeric aporphinoids with structural features rarely seen elsewhere in nature. The caution lies in the realization that decades of fragmented research, spread across species, journals, and methodologies, has produced remarkably little translatable knowledge. Approximately seven in ten studies cannot support firm conclusions, and for most species, the fundamental question of whether any compound can be safely administered to a living animal remains unanswered.

The review thus serves as both inventory and indictment. It confirms that Thalictrum species across Africa and Asia harbor a chemical arsenal of genuine interest to pharmacologists, but it quantifies for the first time how deep the evidentiary gap really is. Whether the strategic framework proposed by Mustapha and colleagues can redirect the field toward controlled, reproducible, mechanistically grounded research will determine whether meadow rue becomes a source of new medicines or remains, like many medicinal plant genera, a library of untested potential. The answer, the authors suggest, will require coordinated investment in isolation chemistry, animal pharmacology, toxicology, and conservation biology, pursued together rather than in the piecemeal fashion that has characterized Thalictrum research to date.

Subject of Research: Phytochemical and pharmacological evaluation of African and Asian Thalictrum species for drug discovery

Article Title: Phytochemical profiles and therapeutic potentials of Thalictrum species in Africa and Asia: a structured review with evidence quality assessment and strategic framework for drug discovery

Article References: Mustapha, S., Mustapha, L., Suciati, S., Govindaraju, K., Ngadimon, I. W., Nordin, M. L., Mohammed, M., Lawal, H., Jibrilla, H. U., Abdulkarim, N., & Azemi, A. K. (2026). Phytochemical profiles and therapeutic potentials of Thalictrum species in Africa and Asia: a structured review with evidence quality assessment and strategic framework for drug discovery. Plant Biosystems, 160(5), Article 250. https://doi.org/10.1007/s44473-026-00263-w

Image Credits: AI Generated

DOI: 10.1007/s44473-026-00263-w

Keywords: Thalictrum, phytochemistry, isoquinoline alkaloids, ethnomedicine, drug discovery, medicinal plants, Ranunculaceae, evidence quality, pharmacology, toxicity, bioassay-guided isolation, Africa and Asia flora

The scale of the problem motivating this reversal is stark. Despite decades of progress, cardiovascular disease remains the leading cause of death worldwide, and the attrition rate in cardiometabolic drug development remains punishingly high. Many agents that showed dramatic effects in animal models of atherosclerosis, heart failure or hypertension produced negligible benefit, or unacceptable toxicity, when they reached human trials. The authors of the new work contend that this is not a failure of chemistry or clinical execution but a failure of translational assumptions: animal models, however refined, cannot fully reproduce human cardiovascular physiology, human genetic variation, or the decades-long natural history of diseases that unfold over a lifetime in people.

The human-first proposal inverts the classical sequence. Rather than beginning with a hypothesis generated in a model system, investigators begin with comprehensive molecular measurements drawn directly from human populations — genomes, transcriptomes, proteomes, metabolomes, epigenomes and, increasingly, single-cell profiles of human cardiovascular tissue. These layers of ‘omics’ data are then integrated computationally to reveal which genes, pathways and cell types are genuinely perturbed in human disease. Only after such human-grounded signals are identified does the work move toward experimental validation, drug targeting and therapeutic design. In effect, the clinic and the population study become the source of hypotheses, and the laboratory becomes the venue for testing them.

Each omics layer contributes a different kind of evidence. Genome-wide association studies have already delivered hundreds of genetic loci linked to myocardial infarction, atrial fibrillation, cardiomyopathy and related traits, but most of these associations point to non-coding regions of the genome whose function is unknown. Transcriptomics converts those static genetic signals into dynamic statements about which genes are actively expressed in diseased hearts and vessels. Proteomics captures the actual effector molecules of biology — the proteins that drugs must engage — while metabolomics offers a real-time readout of cellular chemistry and environmental influence, including diet, microbiome activity and medication effects. Epigenomic profiling explains how risk is encoded not only in DNA sequence but in the regulation of gene activity across a lifetime.

The real power, the authors argue, emerges from integration. No single omics layer is sufficient, because each is noisy, incomplete and context-dependent, but convergent evidence across layers can separate true disease biology from statistical artifact. If a genetic variant associated with coronary artery disease falls in a regulatory region that is active specifically in human vascular smooth muscle cells, and if the gene it controls shows altered expression and altered protein abundance in diseased tissue, and if metabolites in the same pathway track with disease severity, the case for that pathway’s causal involvement becomes far stronger than any single measurement could provide. Multi-omics integration is thus a way of triangulating on human disease mechanisms with a confidence that single-technology studies rarely achieve.

Recent technological advances have made this vision practical in a way it was not a decade ago. Single-cell RNA sequencing can now resolve the cellular composition of human heart tissue cell by cell, revealing disease-specific states in cardiomyocytes, fibroblasts, endothelial cells and immune cells that bulk measurements average away. Spatial transcriptomics preserves the anatomical context of gene expression, showing not just which cells are involved but where they sit within the architecture of a plaque or an infarcted wall. Long-read sequencing is closing gaps in genome annotation. Mass spectrometry has pushed proteomics toward near-comprehensive coverage of the human proteome. Meanwhile, large biobanks linked to electronic health records — containing hundreds of thousands of participants with genetic data and longitudinal clinical outcomes — provide the population-scale foundation on which human-first discovery depends.

Human pluripotent stem cell technologies supply the experimental counterpart to these population resources. Induced pluripotent stem cell-derived cardiomyocytes and vascular cells allow investigators to model an individual’s genetic background in a dish, testing how specific risk variants alter cell behaviour under controlled conditions. When combined with CRISPR-based gene editing, these systems permit precise causal tests: take a human variant identified through population omics, introduce or correct it in human cells, and observe the consequences. This closes the loop of the reversed pipeline, in which human observation generates the hypothesis and human-derived experimental systems validate it before any animal model or clinical trial is considered.

The therapeutic implications are already visible in recent cardiovascular successes that followed this logic in reverse. PCSK9 inhibitors emerged from human genetics — people with loss-of-function variants in the gene had low LDL cholesterol and reduced heart attack risk — rather than from animal screening. The discovery that elevated lipoprotein(a) is causally linked to aortic stenosis and coronary disease came from human cohort genetics, and drugs targeting that protein are now in late-stage trials. Angiotensin-related pathways, inflammation-driven residual risk identified through human trial data with canakinumab, and genetic validation of targets for heart failure all illustrate the same principle: targets grounded in human evidence have repeatedly outperformed targets chosen on model-organism grounds alone.

The authors are careful to note the substantial challenges that remain. Multi-omics datasets are expensive, and most existing data come from populations of European ancestry, raising urgent questions about equitable generalisation. Integrating heterogeneous data types requires statistical and computational methods that are still maturing, and correlational signals at population scale do not automatically establish causation. Human tissue, particularly healthy and early-disease cardiac tissue, is difficult to obtain, and much of what is available comes from end-stage disease or organ donors, limiting the view of how cardiovascular disease begins. Privacy and consent frameworks for deeply characterised human data remain an active area of policy development. The human-first approach, in other words, demands infrastructure — biobanks, computational platforms, tissue networks and diverse cohorts — as much as it demands new biology.

Even so, the strategic argument is compelling and timely. The pharmaceutical industry has invested heavily in human genetics and real-world data precisely because traditional pipelines have underdelivered in cardiometabolic disease. Academic consortia assembling multi-omics atlases of the human heart and vasculature are generating public resources that any laboratory can interrogate. Artificial intelligence and machine learning, trained on integrated human datasets, are beginning to predict gene function, prioritize drug targets and identify patient subgroups that classical diagnostics lumped together. The human-first framework unifies these developments into a coherent discovery philosophy: measure human biology comprehensively, infer mechanism from the data, validate in human-derived systems, and only then build the therapeutic. If the approach continues to deliver, the pipeline that once flowed from bench to bedside may increasingly be understood as flowing the other way — with the patient, and the population, at its source.

Subject of Research: A human-first multi-omics strategy for cardiovascular disease discovery

Article Title: Reversing the pipeline: a ‘human-first’ multi-omics approach to cardiovascular discovery

Article References: Reversing the pipeline: a ‘human-first’ multi-omics approach to cardiovascular discovery. (n.d.). https://doi.org/10.1038/s12276-026-01835-8

Image Credits: AI Generated

DOI: 10.1038/s12276-026-01835-8

Keywords: cardiovascular disease, multi-omics, human genetics, drug discovery, genomics, proteomics, metabolomics, single-cell sequencing, precision medicine, translational research, Reversing, pipeline

The journey begins in New York, where Founder and Chief Executive Officer Dr. Alex Zhavoronkov will attend the Morgan Stanley 24th Annual Global Healthcare Conference from September 14 to 16. On September 15 at 14:35, Zhavoronkov is scheduled to participate in an in-person fireside chat, engaging global investors and industry leaders on the company’s latest advances in generative AI-driven drug discovery, aging clocks and anti-aging interventions. The Morgan Stanley conference is widely regarded as one of the largest and most influential healthcare investment gatherings in the world, convening thousands of leaders each year, from multinational pharmaceutical companies and biotech innovators to medical device makers, digital health pioneers, hedge funds, long-only investors, consulting firms and regulatory bodies. Its mix of keynote addresses, fireside chats, one-on-one investor meetings and forward-looking roundtables makes it a core venue where international capital identifies healthcare opportunities and where large pharmaceutical companies scout innovative technologies and potential acquisition targets.

For Zhavoronkov, the New York appearance is an opportunity to present Insilico’s progress to the capital markets at a moment of unusual momentum. The company has been steadily expanding its narrative beyond a single headline asset, highlighting an end-to-end autonomous laboratory roadmap that pairs its generative chemistry platforms with laboratory automation designed to compress the timelines of target identification, molecular design and preclinical validation. The aging research dimension of the company’s work, including its well-known deep learning aging clocks that estimate biological age from multimodal data, has long differentiated Insilico from AI drug discovery peers, and executives are expected to weave that longevity science perspective into their dialogue with investors who increasingly view aging biology as a fertile ground for new therapeutics.

From New York the focus shifts to the Middle East. Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to the Riyadh Global Medical Biotechnology Summit, known as RGMBS 2026, running September 14 to 16 in the Saudi capital. On September 16, from 09:00 to 12:00 at the Sofitel Riyadh Hotel and Convention Center, Aliper will lead the Insilico team in hosting a hands-on workshop titled Model Context Protocol-Empowered Protein Design: Combining AI Foundation Models and Physics-Based Molecular Modelling. The session is designed to be intensely practical. Participants will gain first-hand experience using the Model Context Protocol, or MCP, to connect AI foundation models, molecular simulation engines and chemical databases. The curriculum covers the complete workflow from protein and ligand structure preparation through physics-based validation, teaching attendees how to score and prioritize drug candidates with AlphaFold, RDKit and OpenMM, how to interpret binding modes, kinetics and free-energy calculation results, and how to run a directed MCP workflow inside Insilico’s Chemistry42 sandbox environment.

The choice of technical material is significant. The Model Context Protocol has emerged as an open standard for connecting large AI models with external tools and data sources, and Insilico’s workshop represents one of the most concrete demonstrations of how that architecture can be applied to protein engineering and small-molecule discovery. By linking generative foundation models to physics-based simulation, the workflow aims to marry the speed and creativity of deep learning with the rigor of molecular mechanics, free-energy perturbation and kinetics analysis that medicinal chemists have long demanded. Aliper, who has spent much of his career at the intersection of AI-driven drug discovery, frontier biomedical science and cross-disciplinary tool integration, will also use the summit to showcase Insilico’s role in building the Chemistry42 generative chemistry platform and the company’s broader autonomous laboratory ecosystem, positioning the workshop as a window into how modern AI-native biopharma companies orchestrate computational and experimental workflows.

RGMBS 2026 itself carries strategic weight. Co-initiated by the Saudi Ministry of Health, the Royal Commission for Riyadh City and leading biomedical authorities, the summit is one of the largest international biotechnology and medical innovation gatherings in the Middle East. It convenes scientists, research and development leaders, clinical experts, regulators and strategic investors spanning biopharmaceuticals, gene and cell therapy, medical devices, digital health and fundamental life sciences. Organizers have centered the program on frontier biotechnology, precision medicine, AI-driven drug discovery, translational medicine, health-tech investment and biomanufacturing, using keynote addresses, themed workshops, closed-door sessions, industry matchmaking and project roadshows to drive cross-regional collaboration. For global biopharma companies, the event is increasingly viewed as a gateway to the Middle East market and to Saudi Vision 2030, the kingdom’s national strategy that places biomedical capability among its economic diversification priorities.

The third stop brings Insilico to Shanghai, where Co-CEO and Chief Scientific Officer Dr. Feng Ren will attend Bio-Shanghai Week 2026, an event anchored by Zhangjiang Drug Valley, a national-level biopharmaceutical industry hub. On September 17 at 15:00, during the opening ceremony’s AI-Driven Innovation session, Ren will engage in an in-depth dialogue with Professor Michael Levitt, the 2013 Nobel Laureate in Chemistry and Stanford University structural biology professor, on the theme of AI-driven global innovation in therapeutic target discovery and treatment technologies. The conversation is expected to traverse three dimensions: foundational science breakthroughs, industrial translation pathways and global strategic coordination, examining how artificial intelligence is systematically reshaping the full chain from target discovery through molecular design to clinical development. Ren, regarded as one of the leading scientists driving AI-enabled drug research and clinical translation in China, will share Insilico’s generative AI platform, its pipeline progress and the company’s global footprint, creating what organizers describe as a high-level exchange between a leading Chinese AI-driven pharmaceutical company and a top global scientist.

Bio-Shanghai Week ranks among the largest and most internationally influential biopharmaceutical industry events in Shanghai, drawing leading scientists, clinical experts, multinational pharmaceutical and biotech companies, innovative drug and device developers, investors, regulators and industry service platforms. Its agenda spans AI-driven innovation, gene and cell therapy, antibodies and antibody-drug conjugates, rare diseases, neuroscience, global market access, clinical translation and the broader industry ecosystem. The event serves as a vital window into the frontier of China’s biopharmaceutical industry and the wider Yangtze River Delta innovation ecosystem, a region that has become one of the world’s densest concentrations of drug discovery talent and capital.

The final leg of the tour takes Zhavoronkov to Boston on September 18 for the Harvard IvyTech Discussion, co-initiated by Harvard University and other Ivy League academic institutions. From 10:50 to 12:00, he will deliver a keynote address in a forum titled A Geo-Economic Shift: China’s Rise as an Innovation Powerhouse in Biotech. Sharing the stage with leading scientists, industry strategists and policy researchers from North America’s top institutions, Zhavoronkov will discuss the leapfrog transformation of China’s biopharmaceutical industry from generic manufacturing to first-in-class innovation, and the corresponding evolution of the global biopharma value chain and capital landscape. He is also expected to present Insilico’s strategic blueprint as what the company calls a bridge enterprise connecting Eastern and Western innovation ecosystems, spanning Chinese foundational research, the company’s AI platform technology, its global research and development pipeline, and its international capital and industry partnerships. The IvyTech platform, which focuses on frontier technology, industrial transformation and geo-economic topics, brings together scientists, technology executives, entrepreneurs, policymakers and institutional investors for dialogue across biomedical innovation, artificial intelligence, advanced manufacturing, the energy transition and cross-border innovation ecosystems.

The speaking tour arrives at a pivotal financial and scientific moment for Insilico Medicine. The company recently reported total revenue of approximately 106 million US dollars in the first half of 2026, a 287 percent year-over-year increase, and achieved its first profitable half-year since listing, with adjusted net profit exceeding 51 million dollars. The milestone was driven by a series of out-licensing, co-development and research collaborations with global partners including Eli Lilly, Servier, Takeda, SK Biopharmaceuticals, Qilu Pharmaceutical, Hygtia Therapeutics, CMS and Tenacia. As of the latest practicable date, the total contract value of transactions announced by the company in 2026 reached approximately 7.3 billion dollars, pushing the cumulative contract value of its major collaborations since 2021 to roughly 11 billion dollars. On the research front, Insilico nominated nine development candidates within the first nine months of 2026 as of late August, a company record for annual pipeline productivity, and achieved eight clinical milestones across its proprietary and co-developed programs. Leading that progress is rentosertib, also known as ISM001-055, the world’s first drug candidate discovered and developed using generative AI, which has advanced into a Phase III trial evaluating treatment for idiopathic pulmonary fibrosis, a progressive and often fatal scarring lung disease with few therapeutic options. Listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 under the stock code 03696.HK, Insilico continues to apply its Pharma.AI platform to fibrosis, oncology, immunology, pain, obesity and metabolic disorders, while extending the technology into advanced materials, agriculture, nutritional products and veterinary medicine. The four-city executive tour, spanning capital markets in New York, biotechnology diplomacy in Riyadh, scientific dialogue in Shanghai and academic strategy in Boston, functions as a compressed portrait of the company’s thesis: that generative AI, rigorous physics-based validation and global collaboration can deliver better drugs faster, and that the companies able to bridge the world’s major innovation hubs will define the next decade of biopharmaceutical progress.

Subject of Research: Insilico Medicine executive participation in four global healthcare and AI summits showcasing generative AI drug discovery

Article Title: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits

Article References: Across four global innovation hubs: Insilico Medicine executive team to speak at premier healthcare and AI Summits. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Insilico Medicine, generative AI, drug discovery, rentosertib, AlphaFold, Model Context Protocol, aging clocks, biotechnology, idiopathic pulmonary fibrosis, AI summits, autonomous laboratory, biopharmaceutical innovation

Abstracting and indexing is the infrastructure that underpins the modern scientific record. When a journal is accepted into a major citation index, its articles become discoverable through the databases that scientists, clinicians, and institutions rely on every day to survey the literature. The Science Citation Index Expanded, maintained within the Web of Science platform, is one of the most selective and influential of these databases. Inclusion signals that a journal has passed rigorous editorial evaluation covering publishing standards, peer-review integrity, international editorial breadth, and citation behavior. For a journal to be abstracted and indexed in SciSearch from 2021 onward means that every article it publishes is now woven into the global web of citation data that powers literature searches, systematic reviews, bibliometric analyses, and institutional assessments.

The consequences of that inclusion ripple outward quickly. A paper on a novel nanoparticle formulation or a new approach to oral drug absorption that might once have been seen primarily by the journal’s existing readership can now surface in the reference lists, alerts, and search results of researchers on every continent. Citations accumulate, and those citations feed directly into the journal’s Impact Factor, the most scrutinized single number in scholarly publishing. The 2022 Impact Factor of 5.5 for the Journal of Pharmaceutical Investigation reflects the average number of times articles published in the preceding two years were cited during 2022. Crossing the threshold into double-digit percentile territory in a crowded category is a meaningful achievement that reflects both the quality of the work the journal publishes and the engagement of the community that reads it.

The ranking attached to that Impact Factor deserves particular attention. The Journal of Pharmaceutical Investigation’s position of 48 out of 278 journals in the Pharmacology and Pharmacy category places it in the Q1 band, the top quartile of its discipline. Quartile rankings divide a category’s journals into four groups by citation performance, and Q1 status is frequently used by funding agencies, hiring committees, and universities as shorthand for excellence. In a field as broad and competitive as pharmacology and pharmacy, which spans everything from medicinal chemistry and pharmacokinetics to clinical pharmacy practice and health economics, occupying the top quartile requires a journal to be cited at rates that exceed roughly three-quarters of its peers. That is a demanding standard in a category where established, decades-old titles compete for the same citations.

Understanding why these metrics matter requires a look at how scientific visibility actually works. Researchers cannot read everything; the volume of pharmaceutical literature published each year runs to hundreds of thousands of articles. Search engines, recommendation tools, and citation databases act as filters, and journals that are indexed in the major databases are dramatically more likely to appear in those filters. An article that is not indexed is, for practical purposes, invisible to much of the global research community, no matter how rigorous its methods or how important its findings. Indexing in SciSearch therefore functions as a guarantee of discoverability, ensuring that the pharmaceutical research published in the journal can be found by the translational scientists, formulation chemists, regulatory affairs professionals, and clinicians who might build on it.

For authors, the practical implications are considerable. Early-career scientists choosing where to submit their work weigh the visibility of a journal heavily, because citations shape careers: grant applications, promotions, and tenure decisions all lean on publication records. A journal with a 5.5 Impact Factor and a Q1 ranking offers a persuasive combination of reach and prestige, particularly for interdisciplinary work in drug delivery, pharmacokinetics, and pharmaceutical technology where the readership spans pharmacy, chemistry, materials science, and medicine. Authors also gain the assurance that their work will be captured in institutional repositories, reported in faculty citation profiles, and counted in national research assessments that draw on Web of Science data.

For readers and research institutions, indexing and citation metrics serve a different but equally important function: they act as quality signals in an environment of information overload. Libraries use indexing status and citation performance to make subscription decisions, allocating finite budgets toward journals that their communities actually use and cite. Systematic reviewers and meta-analysts, whose syntheses of the literature inform clinical guidelines and regulatory decisions, depend on indexed databases to ensure their searches are comprehensive. When a journal is reliably indexed, reviewers can trust that its content will be captured in their search strategies, reducing the risk that important evidence is overlooked. In pharmaceutical research, where a missed finding can influence drug development decisions with billions of dollars and patient safety at stake, that reliability carries real weight.

The journal’s trajectory also illustrates broader dynamics in scholarly publishing. Impact Factors are recalculated annually and can shift with changes in a field’s citation culture, the timing of highly cited articles, and the growth of a journal’s readership. A journal that earns a strong Impact Factor often enters a virtuous cycle: greater visibility attracts stronger submissions, stronger submissions attract more citations, and more citations reinforce the metrics that drew authors in the first place. Entering the Science Citation Index Expanded in 2021 gave the Journal of Pharmaceutical Investigation access to exactly this cycle, and the 2022 figure of 5.5 provides early evidence that the cycle is turning favorably. Sustaining that position will depend on continued editorial rigor, timely publication, and the ability to anticipate where pharmaceutical science is heading next.

Pharmaceutical investigation itself is a field in the midst of remarkable ferment, and the research indexed under this journal’s banner reflects that energy. Drug delivery science is being reshaped by lipid nanoparticles, antibody-drug conjugates, and mRNA platforms whose importance the pandemic made unmistakable. Pharmacokinetic modeling increasingly incorporates artificial intelligence and physiologically based simulation to predict human outcomes from preclinical data. Formulation scientists are tackling biologics, cell therapies, and nucleic acid medicines that defy the traditional tools of the discipline. A Q1-ranked journal embedded in this landscape functions as a convergence point, drawing together the pharmacists, chemical engineers, clinicians, and data scientists whose combined work determines whether laboratory discoveries become medicines on pharmacy shelves.

As the Journal of Pharmaceutical Investigation continues its indexed run, its citation record will be watched not only by its editors and authors but by the wider community that relies on bibliometric indicators to navigate an expanding literature. The 2022 Impact Factor of 5.5 and the Q1 rank of 48 out of 278 in Pharmacology and Pharmacy establish a clear benchmark, and they assure researchers that work published in the journal will be counted, cited, and seen. In a scientific ecosystem where discoverability can determine whether a finding shapes a new therapy or fades unread, the combination of rigorous peer review, inclusion in the Science Citation Index Expanded, and strong citation performance represents the difference between publishing and truly communicating. For pharmaceutical science, one of the most consequential research endeavors of the age, that distinction matters.

Subject of Research: Abstracting, indexing, and citation performance of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, impact factor, Science Citation Index Expanded, SciSearch, Web of Science, pharmacology, pharmacy, Q1 journal, citation metrics, drug delivery, scholarly publishing, pharmaceutical sciences

To understand why this matters, it helps to unpack what abstracting and indexing actually involves. Abstracting services capture the summary, or abstract, of each article along with its metadata: authors, affiliations, keywords and journal details. Indexing goes a step further, embedding that metadata into structured databases that can be searched, cross-referenced and analyzed at scale. The Science Citation Index Expanded, maintained by Clarivate as part of the Web of Science Core Collection, is among the most selective of these databases. Journals are admitted only after an editorial evaluation that examines editorial rigor, peer-review integrity, the international diversity of authorship, regularity of publication and the citation behavior of the published content. Once a journal is accepted, every article it publishes is ingested, its reference list is parsed, and each cited reference is linked to the database’s network of scholarly records.

That reference linking is what makes citation metrics possible. When a paper published in the Journal of Pharmaceutical Investigation is cited by a researcher anywhere in the indexed literature, the event is recorded, timestamped and attributed. Aggregated over time, these events feed the Journal Impact Factor, a metric calculated annually in Clarivate’s Journal Citation Reports. The formula is deceptively simple: the 2022 impact factor counts citations made in 2022 to items the journal published in 2020 and 2021, divided by the number of citable items, typically articles and reviews, published in those same two years. A score of 5.5 therefore means that, on average, each citable paper from the journal’s 2020 and 2021 volumes was cited 5.5 times in the following year by the indexed literature.

The category ranking adds a second layer of interpretation. Pharmacology and Pharmacy is one of the largest and most competitive categories in the Journal Citation Reports, containing 278 journals that range from basic molecular pharmacology to clinical therapeutics and formulation science. Ranking 48th in that field places the journal in the 17th percentile, comfortably inside the Q1 quartile that spans the top 25 percent of titles. Quartile assignments matter in practical academic life: hiring committees, grant agencies and national evaluation systems in many countries use Q1 status as a shorthand for journal prestige, and some funding bodies explicitly require that publications appear in Q1 or Q2 journals to count toward a researcher’s track record.

For a journal focused on pharmaceutical investigation, the indexing milestone also changes how its content circulates. Articles in the Science Citation Index Expanded are surfaced through Web of Science searches used daily by millions of researchers, and the indexed metadata feeds into citation alerts, research profiles and institutional dashboards. Downstream services, including citation managers, discovery layers at university libraries and literature-screening tools used in drug-safety reviews, draw on the same structured records. In practical terms, a pharmacokinetics study or a novel drug-delivery paper published in the journal is now far more likely to be found, cited and built upon by teams working in formulation chemistry, clinical pharmacy and regulatory science around the world.

The timing is notable against the backdrop of a broader debate about how scientific quality should be measured. The impact factor, conceived in the 1960s as a tool for librarians deciding which journals to subscribe to, has become one of the most scrutinized numbers in science. Critics, including the signatories of the San Francisco Declaration on Research Assessment, argue that the metric is easily skewed by a small number of highly cited papers, that it differs across fields in ways that make cross-disciplinary comparisons misleading, and that it says nothing about the quality of any individual article. Defenders counter that, for all its flaws, the impact factor remains a transparent, reproducible and widely understood indicator of a journal’s average citation performance, and that quartile rankings within a single field, such as Pharmacology and Pharmacy, offer a fairer like-for-like comparison.

Clarivate itself has been evolving the ecosystem around these metrics. In recent years the Journal Citation Reports have added supplementary indicators, including the Journal Impact Factor percentile, the five-year impact factor and the Eigenfactor-style measures that weight citations by the prestige of the citing journal. The 2023 release extended impact factors to all journals in the Web of Science Core Collection, including those in the Emerging Sources Citation Index, a change that increased the number of titles receiving the metric from roughly 9,500 to more than 21,000. For newly indexed journals, this expansion means that citation performance is visible almost immediately after entry into the collection, rather than after the traditional multi-year waiting period, accelerating the feedback loop between publication and measurable scholarly impact.

Behind the headline numbers lies a labor-intensive editorial operation. Journals seeking Science Citation Index Expanded inclusion must demonstrate consistent publication schedules, robust peer-review processes, ethical publishing practices aligned with guidelines from the Committee on Publication Ethics, and content that is genuinely international in authorship and readership. Clarivate’s editorial development team also assesses whether the journal fills a distinctive niche relative to existing coverage, a criterion that rewards publications addressing specific research communities, such as pharmaceutical formulation, biopharmaceutics and translational drug research, rather than duplicating well-served areas. Once admitted, journals remain under continuous review, and titles whose quality or citation performance deteriorates can be flagged or delisted, a mechanism that has drawn increased attention as the publishing industry confronts paper mills and predatory outlets.

For researchers deciding where to submit their work, the combination of Q1 status and a 5.5 impact factor signals that the journal now competes directly with established titles in pharmaceutical science. Authors in drug delivery and pharmaceutical technology often weigh several factors beyond the impact factor: the speed of peer review, open-access options and licensing terms, the journal’s readership among industrial and regulatory scientists, and how quickly an accepted paper becomes visible in indexing services. Full indexing in the Science Citation Index Expanded addresses the visibility component decisively, since every accepted article enters the citation network from the point of indexing onward, accumulating the references that will determine future metric cycles.

The broader lesson from the journal’s trajectory is that scholarly visibility is built in layers: rigorous peer review attracts strong papers, strong papers attract citations, citations drive impact factors, and impact factors, in turn, attract more strong submissions. Indexing in the Science Citation Index Expanded is the infrastructure that makes this cycle measurable. As the 2023 and 2024 publication years accumulate citations, the journal’s position within the Pharmacology and Pharmacy rankings will be tested against 277 competitors, many of them far larger and longer-established. Whether it consolidates its Q1 standing or climbs higher, its entry into the citation mainstream marks the moment when its research output became fully countable in the quantitative machinery that increasingly shapes careers, funding decisions and the global flow of pharmaceutical science.

Subject of Research: Abstracting and indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its Q1 impact factor ranking in pharmacology

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Science Citation Index Expanded, Web of Science, Journal Impact Factor, Clarivate, Q1 journal, Pharmacology and Pharmacy, citation analysis, abstracting and indexing, pharmaceutical science, research metrics, peer review

To understand why this matters, it helps to unpack what indexing in the Science Citation Index Expanded actually means. The Science Citation Index Expanded is one of the core citation databases maintained within the Web of Science, the citation ecosystem originally built on Eugene Garfield’s pioneering work at the Institute for Scientific Information. Inclusion is not automatic. Journals seeking coverage undergo a rigorous evaluation process in which publishers submit documentation of editorial standards, peer review practices, editorial board composition, publication ethics policies, and the international diversity of authorship. Clarivate’s editorial development team assesses whether the journal meets the quality thresholds for foundational coverage and whether its citation performance justifies admission. Being accepted into SciSearch in 2021 signaled that the Journal of Pharmaceutical Investigation had cleared one of the most demanding quality gates in scholarly publishing, a gate that thousands of journals worldwide never pass.

Indexing, in turn, is the precondition for the metric that has become the lingua franca of journal evaluation: the Impact Factor. Calculated annually by Clarivate from the Journal Citation Reports, the Impact Factor for a given year counts the number of citations received in that year by items published in the journal during the two preceding years, divided by the number of citable items published in those same two years. A value of 5.5 for 2022 therefore means that, on average, each citable article published in the journal during 2020 and 2021 was cited 5.5 times in 2022. Because the journal entered SciSearch in 2021, this figure reflects a relatively early citation window, which makes the performance even more striking. New entrants to the citation index typically take several years to accumulate visibility, so a first-quartile placement so soon after admission suggests an unusually rapid adoption by the research community.

The quartile classification adds another layer of meaning. Clarivate assigns journals to categories, and within each category journals are ranked by their Impact Factor and divided into quartiles, with Q1 representing the top 25 percent of titles. The Pharmacology and Pharmacy category is one of the largest and most competitive in the entire Web of Science taxonomy, encompassing 278 journals that range from mega-journals of translational medicine to highly specialized publications in toxicology, drug metabolism, and clinical pharmacy. Ranking 48th in that field places the Journal of Pharmaceutical Investigation firmly within the upper tier of pharmacological publishing, alongside far more established titles with decades of citation history. For authors weighing where to submit manuscripts, quartile placement often carries practical consequences, because funding agencies, promotion committees, and doctoral programs in many countries explicitly require publication in Q1 journals.

The journal’s subject scope helps explain its rising citation profile. Pharmaceutical investigation as a discipline sits at the crossroads of pharmaceutics, biopharmaceutics, drug delivery, pharmacokinetics, and formulation science, and it increasingly absorbs techniques from nanotechnology, materials science, and computational modeling. Research published under this umbrella includes studies of controlled-release systems, lipid-based carriers, polymeric nanoparticles, dissolution testing, bioavailability enhancement, and the physicochemical characterization of novel dosage forms. In recent years the field has been swept up in broader currents reshaping the pharmaceutical sciences, including the explosion of interest in mRNA delivery platforms, the refinement of long-acting injectable formulations, and the application of machine learning to formulation optimization. Journals positioned at the center of these currents tend to attract high citations, because their articles serve as methodological references for large and fast-moving research communities.

The journal in question is published by Springer, one of the major international scientific publishers, and the pharmaceutical sciences have long been a strategic area for the company’s portfolio. The relationship between publisher and index provider is central to the economics of modern scholarly communication. Publishers invest in editorial infrastructure, peer review management, digital preservation, and dissemination platforms, while citation index providers aggregate the resulting literature into evaluative frameworks that institutions use to allocate resources. The feedback loop can be powerful. Indexing increases discoverability through Web of Science searches, discoverability drives downloads and citations, and citations raise the Impact Factor, which in turn attracts stronger submissions from researchers seeking maximum visibility for their work. The journal’s 2022 numbers suggest that this flywheel has begun to turn decisively.

It is worth pausing on how rapidly scholarly metrics themselves have evolved, because the Impact Factor, despite its ubiquity, is a blunt instrument. Critics have long noted that the two-year citation window disadvantages slow-moving fields, that citation distributions within journals are heavily skewed so that a small fraction of papers accounts for most citations, and that aggregate scores can be gamed through editorial strategies such as publishing review articles, which attract citations at a higher rate than primary research. The San Francisco Declaration on Research Assessment, signed by thousands of journals and institutions, urges evaluators to look past journal-level metrics to the actual content and quality of individual papers. Yet the practical reality in much of the world, particularly in Asia, Europe, and Latin America, is that Impact Factors and quartiles remain embedded in grant applications, hiring decisions, and national research assessment exercises. Against that backdrop, a journal’s climb into Q1 translates directly into the career incentives of working scientists.

The pharmaceutical sciences occupy a distinctive position in this evaluative landscape because the field straddles academia and industry. Research on drug delivery and formulation frequently progresses from laboratory bench to clinical application, and the intellectual property and commercial stakes involved mean that citation patterns differ from those in purely academic disciplines. Industry scientists read and cite the pharmaceutical technology literature when designing development programs, and regulatory science considerations, such as bioequivalence standards and dissolution specifications, generate steady citation demand for foundational methodology papers. A Q1 journal in this space therefore functions not only as an academic outlet but as a shared reference point connecting university labs, contract research organizations, generic drug manufacturers, and innovator pharmaceutical companies across dozens of countries.

The timeline of the journal’s ascent is also instructive for understanding how new journals break through in a crowded market. Acceptance into SciSearch in 2021 followed the standard probationary logic of the Web of Science: emerging journals receive partial coverage initially, typically tracking newly published content, and their citation records build as indexed material accumulates. Within a single full cycle the journal achieved an Impact Factor of 5.5 and a category rank of 48 of 278, performance that many long-established titles would consider strong. This acceleration is characteristic of the current era, in which digital distribution, social media amplification, and global submission pipelines allow a well-edited journal to reach its audience far faster than was possible in the print-dominated decades when citation reputations took a generation to form.

For observers of scientific publishing, the broader lesson is that the map of influential journals is not fixed. The Pharmacology and Pharmacy category continues to expand, the tools for evaluating research continue to evolve, and the competition for high-quality manuscripts intensifies as publishers launch new open-access titles and established journals adjust their strategies. The Journal of Pharmaceutical Investigation’s 2022 standing, with an Impact Factor of 5.5 and a first-quartile ranking among 278 pharmacology journals, demonstrates how indexing prestige, editorial focus, and community engagement combine to reshape that map. Whether the journal can sustain and improve its position in future Journal Citation Reports will depend on the same factors that drive all scholarly success: the quality and novelty of the science it publishes, the rigor of its peer review, and its ability to serve as an indispensable resource for the researchers advancing drug development worldwide.

Subject of Research: Indexing and citation performance of the Journal of Pharmaceutical Investigation in the Web of Science Pharmacology and Pharmacy category

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Journal of Pharmaceutical Investigation, Impact Factor, Science Citation Index Expanded, Web of Science, pharmacology, pharmacy, quartile ranking, citation metrics, drug delivery, pharmaceutical sciences, Springer, Q1 journal

The appeal of MOFs begins with their architecture. Metal centers or clusters act as nodes, joined by organic linkers into extended three-dimensional crystalline networks whose pores can be adjusted with near-atomic precision. Because researchers can independently vary the metal, the linker and the functional groups decorating the pore walls, MOFs offer record-breaking internal surface areas, tunable pore sizes and a modular versatility that rigid inorganic adsorbents such as zeolites struggle to match. The review categorizes frameworks into rigid structures suited to molecular sieving, flexible or breathing frameworks whose unit cells expand and contract as guest molecules enter and leave, and surface-functionalized frameworks grafted with groups such as amines, sulfonates or carboxylates that dramatically alter adsorption affinity, hydrophobicity and stability. Open metal sites, generated when coordinated solvent molecules are stripped away during activation, add another handle for tuning performance; the copper framework HKUST-1, for example, adsorbs notably more carbon dioxide in the presence of a small amount of water.

A substantial portion of the review is devoted to how these materials are actually made, because the synthesis route shapes everything from crystallinity to cost. Solvothermal and hydrothermal methods remain the workhorses, producing highly crystalline frameworks such as MIL-101(Cr) and UiO-66, but they demand high temperatures and pressures, large volumes of organic solvents and long reaction times that limit scalability. Microwave-assisted synthesis slashes reaction times and yields uniform nanocrystals with high phase purity, yet scaling microwave equipment to industrial throughput is difficult. Sonochemistry accelerates nucleation with cavitation bubbles that momentarily reach thousands of kelvin, producing nanoscale MOFs with high surface areas, though controlling particle size distribution remains a challenge. Mechanochemical routes grind metal salts and linkers together in ball mills with little or no solvent, offering a genuinely green option at room temperature, at the cost of somewhat lower crystallinity. Electrochemical synthesis, first used by BASF to make HKUST-1 in 2005, supplies metal ions through anodic dissolution of a metal electrode, avoiding corrosive counterions and enabling continuous production. The authors conclude that no method is universally ideal: high crystallinity and tunability favor solvothermal chemistry, while green scalability increasingly points toward mechanochemical and continuous-flow techniques.

In the environmental arena, the review highlights MOFs as adsorbents and catalytic degradation platforms for three major classes of pollutants: synthetic dyes, heavy metals and emerging contaminants. Dye pollution is a serious concern because many residual dyes are carcinogenic and persist in water systems. Frameworks from the UiO, ZIF and MIL families, along with their composites, capture both cationic dyes such as methylene blue, rhodamine B and malachite green and anionic dyes such as methyl orange and congo red. The removal mechanisms operate in synergy: electrostatic attraction between oppositely charged dye molecules and framework surfaces, pi–pi stacking between the aromatic rings of dyes and the organic linkers, hydrogen bonding between surface functional groups and dye molecules, and size-selective pore filling. Because the surface charge of a MOF depends on solution pH and the functional groups present, researchers can engineer adsorbents that switch selectivity simply by decorating the pore walls.

Heavy metals present an even sterner test because they are non-biodegradable and toxic at low concentrations. MOFs bind Pb(II), Cr(VI), As(III/V) and Hg(II) through a combination of ion exchange, surface complexation, chelation, electrostatic interaction and redox conversion. Functionalization with thiol or amine groups markedly boosts selectivity for soft, highly toxic ions such as Hg(II), while redox-active iron-based frameworks can reduce toxic Cr(VI) to the far less hazardous Cr(III), coupling detoxification with immobilization. The review also emphasizes MOF-based membranes, formed when MOF crystals self-assemble on porous supports, which combine tunable pore sizes with high selectivity and recyclability for continuous water purification. The trade-offs are candidly acknowledged: MIL-101(Cr) offers enormous mesoporous cages that handle bulky dye and pharmaceutical molecules, but zirconium-based UiO-66 provides superior chemical robustness, and ZIF-8 resists water yet suffers from narrow pore apertures that restrict diffusion of large contaminants.

The second half of the review turns to biomedicine, where the requirements are far stricter than in industrial applications. An effective MOF drug carrier must encapsulate therapeutics at high loading, degrade in a controlled manner, release its cargo on demand, present acceptable toxicology and lend itself to surface engineering that dictates its fate in the body. MOFs meet these criteria in ways that conventional carriers such as liposomes, mesoporous silica and polymeric nanoparticles often cannot: their surface areas permit exceptionally high drug loading, pores of up to six nanometers accommodate molecules ranging from small-molecule drugs to peptides and large biomolecules, and their relatively weak coordination bonds allow the framework to decompose harmlessly and release its components. Loading can be achieved by diffusion into preformed crystals, by covalent attachment to the external surface, by in situ encapsulation during synthesis, or by using the drug itself as a ligand in framework construction.

Concrete examples illustrate the promise. A chiral zinc-based framework built from triazine-triisophthalate linkers absorbed the anticancer drug 5-fluorouracil through hydrogen bonding at a loading of 0.5 grams per gram and released it slowly over a week in buffered saline. In antibacterial applications, the iron framework MIL-53(Fe) physically loaded the glycopeptide antibiotic vancomycin to nearly 20 percent by weight and, under the acidic conditions that mimic a bacterial infection, released it in a controlled fashion that achieved 99.3 percent efficacy against Staphylococcus aureus while remaining biocompatible in vitro. ZIF-8 has been used to ferry the broad-spectrum cephalosporin ceftazidime, confirmed by element mapping in electron microscopy, and to co-deliver doxorubicin with the P-glycoprotein inhibitor verapamil in folate-targeted, PEG-coated particles that overcame multidrug resistance in tumor cells. A biomimetic nanoreactor combining ZIF-8 with the prodrug tirapazamine, the enzyme glucose oxidase and an erythrocyte membrane coating points toward cancer starvation therapy with improved delivery.

The range of biomedical uses continues to broaden. Copper nanowires sheathed in ZIF-8 slowed the release of antiviral copper ions, showed low cytotoxicity with 99 percent of kidney cells surviving after 48 hours, and were investigated against SARS-CoV-2 in infected cells; surface-functionalized MOFs bearing nystatin, folic acid or tenofovir can bind viral capsid proteins and immobilize viruses. Copper–BTC films grown directly on stent surfaces catalyze the production of nitric oxide from blood-borne s-nitroso-cysteine, improving blood compatibility, while MOF–polymer coatings have been shown to inhibit bacterial attachment to medical tubing under flow. Frameworks delivering ibuprofen to reduce brain inflammation or dopamine for neurological therapy, along with ATP-responsive zirconium systems, extend the concept into chronic disease management, although crossing the blood–brain barrier remains a formidable hurdle.

The review is refreshingly blunt about the obstacles that stand between laboratory success and clinical or industrial deployment. MOF toxicity, driven by metal ion release, particle size, shape and aggregation, can produce oxidative stress, inflammation and organ damage, and standardized toxicity testing protocols and long-term in vivo biocompatibility data are still lacking. Water stability in real treatment streams, biodegradability in physiological settings, regeneration and reuse of adsorbents, material costs and the reproducibility of green synthesis routes all demand further work. Compared with clinically established liposomes and hydrogels, MOFs carry biosafety uncertainty and more complex, expensive synthesis. Yet the trajectory is clear. With defect engineering, biocompatible metal choices, scalable continuous-flow production and rational linking of synthesis conditions to structure–performance relationships, the authors argue, these crystalline cages could become central platforms for sustainable water purification and personalized medicine alike, addressing some of the most pressing environmental and health challenges of the coming decades.

Subject of Research: Metal–organic frameworks for wastewater treatment and targeted drug delivery

Article Title: Emerging roles of metal organic frameworks in wastewater treatment and targeted drug delivery applications

Article References: Singh, P., Singh, G., Singh, C. K., Nitin, V., & Sodhi, K. K. (2026). Emerging roles of metal organic frameworks in wastewater treatment and targeted drug delivery applications. Discover Industrial Chemistry and Materials, 1(1), Article 12. https://doi.org/10.1007/s44508-026-00010-1

Image Credits: AI Generated

DOI: 10.1007/s44508-026-00010-1

Keywords: metal–organic frameworks, MOF synthesis, wastewater treatment, heavy metal adsorption, dye removal, drug delivery, targeted cancer therapy, biocompatibility, MOF membranes, stimuli-responsive release, antibacterial agents, water purification

Abstracting and indexing may sound like a dry administrative exercise, but for working scientists it is the infrastructure that determines whether their work is ever seen. When a journal is indexed in a major citation database, every published article gains a standardized record: a structured abstract, author affiliations, subject headings, bibliographic metadata and, critically, a persistent link that other researchers can follow from a search result to the full text. Without that record, even excellent research risks becoming invisible, buried in a journal that search engines and literature reviews rarely surface. Indexing is therefore the mechanism by which a journal’s content enters the bloodstream of scientific communication.

Science Citation Index Expanded, maintained within the Web of Science ecosystem, is one of the most selective and widely recognized of these databases. Journals admitted to the index undergo evaluation of their editorial rigor, publishing standards, peer-review processes, international authorship and citation behavior. Inclusion since 2021 means that all content published by the Journal of Pharmaceutical Investigation from that point onward is systematically captured, allowing citation links to accumulate year by year. This is a prerequisite for any journal that hopes to receive a Journal Impact Factor, the most discussed single number in scholarly publishing.

The Journal Impact Factor itself is a deceptively simple calculation. In any given year, it counts the citations received in that year by items a journal published in the two preceding years, divided by the number of substantive, citable items, chiefly research articles and reviews, published in those same two years. A 2022 impact factor of 5.5 therefore reflects citations earned during 2022 by material published in 2020 and 2021. That figure indicates that, on average, each citable article from those years was cited more than five times within the measurement window, a level of citation intensity that places the journal firmly among the most influential publications in its discipline.

Just as significant as the raw score is the category ranking: 48th out of 278 journals in Pharmacology and Pharmacy. Citation density varies enormously between fields, so a raw impact factor means little until it is contextualized within a discipline. Quartile placement provides that context. A first-quartile position, corresponding to the top 25 percent of journals in the category, signals to authors, reviewers, librarians and funding bodies that the journal sits within the leading tier of venues for pharmaceutical research. It is this rank, rather than the number alone, that most often determines where researchers choose to submit their best work.

For pharmaceutical scientists, the practical consequences are concrete. A Q1 journal with a 5.5 impact factor becomes a preferred destination for studies on novel drug delivery systems, pharmacokinetics, formulation science, nanotechnology-based therapeutics and clinical investigation of new compounds. Authors gain the assurance that their papers will be read by a broad, international audience and that citations will be tracked and attributed correctly. Readers gain the assurance that the journal’s editorial standards have been vetted by an independent indexing body. Institutions, in turn, use these indicators when evaluating faculty productivity, since indexed, highly ranked publications carry more weight in hiring, promotion and grant assessments.

The timing of the indexing also matters. A journal’s early years in a citation index are typically characterized by incomplete citation trails, because it takes time for the database to record references pointing back to newly indexed content. As the 2021 entry point recedes, successive impact factor cycles will draw on an increasingly complete record of the journal’s output. This dynamic often produces a period of citation growth, as previously published articles continue to accrue citations while the denominator of citable items stabilizes. The 2022 figure of 5.5 should therefore be read not as a static endpoint but as a data point in an ongoing trajectory of the journal’s scientific footprint.

It is worth pausing on why metrics like these attract such intense attention, and also on their limits. The Journal Impact Factor was originally designed as a library-management tool, a way to help librarians decide which journals to subscribe to, not as a measure of the quality of any individual paper. A citation to an article can be positive, negative or merely incidental, and citation counts are influenced by article type, review coverage and field trends. Editors and bibliometricians have long cautioned against grading individual researchers by the impact factor of the journals in which they publish. Nevertheless, at the level of the journal as a whole, the metric remains a fast, transparent and universally understood signal of scholarly influence, and quartile rankings in particular continue to shape real decisions across the research enterprise.

Within pharmaceutical science specifically, the value of strong indexing infrastructure is amplified by the field’s translational character. Research published in these pages informs drug formulation, bioavailability enhancement, controlled-release technology, pharmacoeconomics and regulatory science, and its audience spans academic laboratories, industrial research and development groups, clinical pharmacologists and regulatory reviewers. When a study on a novel nanoparticle carrier or an improved oral delivery platform is properly abstracted and indexed, it can be retrieved by a formulator searching for prior art, by a regulatory scientist drafting a dossier or by a clinician weighing a new therapeutic approach. Each of those retrieval events is a potential citation, and each citation strengthens the record on which the journal’s ranking rests. Indexing, citation and scientific progress form a single feedback loop.

The Journal of Pharmaceutical Investigation’s combined achievement, inclusion in Science Citation Index Expanded since 2021, a 2022 Journal Impact Factor of 5.5 and a Q1 ranking of 48 out of 278 in Pharmacology and Pharmacy, therefore represents more than a publishing success. It reflects the cumulative choices of thousands of authors who selected the journal as the home for their work, the reviewers and editors who upheld its scientific standards, and the researchers worldwide whose citations now register in the databases that measure contemporary science. As the journal’s indexed archive matures, its bibliometric record will continue to evolve, and the pharmaceutical research community will be watching how that trajectory develops in the annual release of citation reports to come.

Beyond the headline numbers, the mechanics of how a journal enters and moves through the citation ecosystem deserve closer attention. Science Citation Index Expanded traces its lineage to the Citation Index for Science created in the 1960s, when bibliographers first demonstrated that references embedded in published papers could be aggregated into a searchable network of scholarly influence. That insight, that citations function as explicit acknowledgments of prior intellectual debt, remains the conceptual foundation of modern bibliometrics, and every impact factor calculated today descends from it.

The distinction between being indexed and being measured is also worth clarifying. Journals admitted to Science Citation Index Expanded receive standardized bibliographic records and become part of the citation network, but the Journal Impact Factor itself is released through a separate annual reporting process that evaluates journals after a period of consistent indexing. This staged progression explains why newly indexed journals often need several annual cycles before their metrics stabilize, and why the 2022 assessment of the Journal of Pharmaceutical Investigation represents an early but meaningful reading of its citation performance rather than a mature one.

For authors deciding where to submit, indexing status interacts with other practical considerations. Pharmaceutical research is a fast-moving field in which preprints, conference proceedings and patent literature all compete for attention, so the assurance that a journal’s records are systematically captured and cross-linked carries real weight. Standardized metadata also enables bibliometric tools to disambiguate authors with similar names, connect related datasets and track the diffusion of a finding across disciplines, functions that become increasingly important as pharmaceutical science grows more interdisciplinary, drawing on chemistry, biology, engineering and clinical medicine simultaneously.

The category in which the journal is ranked deserves note as well. Pharmacology and Pharmacy is a broad and crowded classification that encompasses basic pharmacological research, drug design, clinical therapeutics and pharmacy practice, meaning journals compete for citation attention across quite different audiences. Achieving a position within the top quartile of such a heterogeneous category suggests that the journal’s content resonates beyond a narrow specialty, attracting citations from multiple subfields rather than from a single tightly knit community. Cross-disciplinary citation of this kind is often cited by editors as a sign of durable relevance.

Finally, the broader publishing environment shapes how such metrics should be interpreted. Scholarly communication is undergoing sustained change, with open access models, alternative metrics and funder mandates altering how research is disseminated and discovered. Citation-based measures remain the most established currency of journal evaluation, but they increasingly sit alongside downloads, altmetric attention and policy citations in a fuller picture of impact. Within that evolving landscape, a journal that combines rigorous peer review, international reach and strong indexed performance is well positioned to remain a trusted venue as the standards by which science is assessed continue to develop.

Subject of Research: Abstracting and indexing of pharmaceutical research journals and citation metrics

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, SciSearch, Journal Impact Factor, pharmacology, pharmacy, Q1 journal, citation metrics, Web of Science, pharmaceutical investigation, journal ranking, scholarly publishing

The importance of this challenge is difficult to overstate. Proteins are the molecular machines of life, and most drugs work by binding to specific pockets on protein surfaces, either blocking or modifying their activity. If researchers can predict where these binding sites are located from protein sequence or structure alone, they can accelerate the early stages of drug discovery, anticipate side effects caused by unexpected binding, and even help interpret the function of newly discovered proteins whose roles remain mysterious. The classic computational tools that have been developed over decades to address this question have steadily improved, but they all face a fundamental tension between two different ways of representing a protein: as a linear sequence of amino acids, or as a three-dimensional structure folded into a functional shape.

Sequence-based methods have the advantage of simplicity and broad coverage, since protein sequences are far easier to obtain than high-resolution structures. But they lack explicit spatial awareness; they see the protein as a string of letters, and identifying a pocket that exists only in three-dimensional space is intrinsically difficult from that representation alone. Structure-based methods, on the other hand, can directly interrogate the geometry of a protein, identifying cavities and grooves where small molecules are likely to fit. Yet these approaches have traditionally struggled to integrate information about long-range functional relationships between distant parts of a protein, and they often generalize poorly to proteins that bear little similarity to the training data or that have been only sparsely annotated by experimental studies.

The Qingdao team, led by Minglei Dong and corresponding author Zhen Li, set out to build a framework that could exploit the strengths of both representations while compensating for their individual weaknesses. Their solution is a dynamic–static collaborative multimodal graph learning architecture, a mouthful of terminology that describes a system in which several specialized neural network components work together on different aspects of the protein simultaneously. At its core, the method treats a protein as a graph, with amino acid residues as nodes and relationships between them as edges, but it constructs and processes these graphs in several complementary ways rather than relying on a single representation.

The first component of the framework is a Static Global Sequence Encoding module. This module examines the protein’s amino acid sequence and extracts patterns at multiple scales, from short local motifs that might form part of a binding pocket to longer-range contextual dependencies that span large portions of the protein. By operating on the sequence in this multi-scale fashion, the encoder builds a rich representation of which parts of the protein are functionally significant, even before any structural information is considered. This static encoding serves as a foundation upon which the rest of the architecture builds, providing consistent semantic information about each residue’s role in the overall protein.

The second component, and arguably the most innovative, is the Gated Dual-Graph Dynamic Propagation module, or GDDP. This module simultaneously models two different graphs derived from the protein: a dynamic spatial graph that captures the geometric relationships between residues in three-dimensional space, and an attention-guided sequence graph that captures functional correlations derived from the protein’s primary sequence. By propagating information through both graphs in parallel and using a gating mechanism to control how signals from each graph influence the final residue representations, the module allows the model to adaptively determine, for each residue and each context, whether spatial geometry or sequence-based function should carry more weight in the prediction. This adaptive interaction modeling is what gives DSC-BSite its flexibility, enabling it to make good predictions even on proteins whose structural or sequence characteristics differ substantially from those seen during training.

The third major component is a pre-training strategy the authors call PPI-guided Structural–Semantic Alignment, or PSSA. Pre-training has become a cornerstone of modern machine learning, where models first learn general patterns from large datasets before being fine-tuned on specific tasks. In this case, the researchers used information about protein–protein interactions to teach their model how structural representations should relate to functional semantic embeddings. The key insight is that protein-protein interaction data, which is abundant in public databases, encodes information about which parts of a protein are functionally important, since interacting proteins must contact each other at specific functional sites. By aligning structural features with these function-aware semantic embeddings during pre-training, the model learns structural representations that are biologically meaningful rather than merely geometric. Crucially, the model does not require protein–protein interaction information at inference time, meaning it can make predictions for any protein using only its sequence and structure, without access to the expensive experimental data used during training.

To evaluate their method, the researchers tested DSC-BSite on two benchmark datasets: UniProtSMB and SJC. The results were competitive across multiple evaluation metrics, but the method showed particular strengths in specific areas. On the UniProtSMB dataset, DSC-BSite achieved notably strong performance in Recall, meaning it was especially good at identifying true binding site residues without missing too many. On the SJC dataset, the method excelled in Precision and in the Matthews Correlation Coefficient, or MCC, a comprehensive metric that accounts for true and false positives and negatives simultaneously and is widely regarded as a balanced measure of classifier quality. High Precision indicates that when the model flags a residue as part of a binding site, it is very likely to be correct, which matters enormously in a drug discovery context where computational predictions must ultimately be verified experimentally.

The broader implications of this work extend well beyond the immediate technical achievement. The multimodal philosophy underlying DSC-BSite reflects a growing recognition in computational biology that no single representation of a protein is sufficient to capture its full biological complexity. Sequence tells us about evolutionary conservation and functional motifs. Structure tells us about physical geometry and accessible surface area. Function, as encoded in interaction data, tells us about biological role and context. Methods that can effectively integrate these different layers of information are likely to outperform those that rely on any single source, particularly as the volume and diversity of protein data continue to expand at an astonishing pace.

The timing of this work is also significant. The recent revolution in protein structure prediction, catalyzed by tools such as AlphaFold and ESMFold, has made accurate three-dimensional protein structures available at a scale never before possible. Structure-based machine learning methods can now be trained and evaluated on far larger datasets than was previously feasible. At the same time, protein language models trained on vast numbers of sequences have demonstrated an impressive ability to encode functional information directly from primary sequence data. DSC-BSite sits squarely at the intersection of these two revolutions, leveraging both structural and sequence-derived information in a principled and adaptive manner.

Importantly for the research community, the authors have made their data and source code publicly available through the GitHub repository associated with the project. This commitment to open science means that other researchers can examine, reproduce, and extend the work, potentially adapting the dynamic–static collaborative framework to related problems such as protein–protein binding site prediction, protein–nucleic acid interaction modeling, or even the prediction of allosteric sites that regulate protein activity from distant locations on the protein surface. The gating and dual-graph concepts may also prove useful in other multimodal machine learning applications beyond structural biology.

Challenges certainly remain. Protein binding site prediction, even with sophisticated deep learning approaches, is far from a solved problem, and the low-similarity proteins that motivated this work continue to represent a difficult frontier. Experimental validation of computational predictions remains essential, and the translation of better in silico binding site identification into genuinely accelerated drug discovery pipelines will require continued integration with molecular docking, molecular dynamics simulations, and laboratory screening. Nevertheless, DSC-BSite represents a thoughtful and technically sophisticated contribution to a field that sits at the heart of modern drug development. By demonstrating that dynamic and static graph representations can collaborate effectively, and that pre-training on interaction data can produce more biologically meaningful structural features without burdening inference with additional data requirements, the Qingdao researchers have offered the community both a practical new tool and a conceptual template for future multimodal approaches to protein analysis. As pharmaceutical research increasingly depends on computational methods to navigate the vast space of possible drug targets and molecules, advances of this kind are likely to play a growing role in determining which molecular questions can be answered quickly, cheaply, and accurately.

The rationale for the study rests on the biology of inflammation itself. Rather than being governed by a single molecular switch, inflammatory responses arise from interlocking signaling networks involving cytokines, kinases, and transcription factors that amplify and modulate one another. Drugs aimed at a single target often deliver incomplete benefit, prompting researchers to look for multi-target agents, particularly among natural products that contain mixtures of structurally diverse compounds. The authors framed their investigation around this premise, asking whether the constituents of I. carnea could plausibly act on several nodes of the inflammatory circuitry simultaneously and whether the most promising candidate could withstand computational and biochemical scrutiny.

The first stage of the analysis was network pharmacology, an approach that maps the relationships between candidate compounds, their protein targets, and the disease-relevant pathways those targets populate. From the five phytoconstituents studied, the team identified a set of key inflammatory targets that included TNF, IL6, IL1B, MAPK1, MAPK14, STAT3, and NFKB1. These targets are central players in inflammatory signaling: TNF, IL6, and IL1B are potent pro-inflammatory cytokines; MAPK1 and MAPK14 are mitogen-activated protein kinases that relay stress and cytokine signals; STAT3 is a transcription factor activated by many cytokine receptors; and NFKB1 is a core component of the NF-κB pathway, one of the most important regulators of inflammatory gene expression. Pathway enrichment analysis placed these targets within the NF-κB, TNF, IL-17, JAK-STAT, NOD-like receptor, and FoxO signaling pathways, all of which are well-documented contributors to inflammatory disease processes. The network picture suggested that the I. carnea constituents, if active, would not act at a single point but across a web of interconnected inflammatory mechanisms.

To narrow the field, the researchers turned to molecular docking, a computational technique that predicts how well a small molecule fits into the binding site of a protein and estimates the strength of that interaction through a docking score. The protein chosen for this exercise was the receptor represented by the Protein Data Bank entry 3HA8, a structure commonly used in inflammation-related docking studies. When all five phytoconstituents were docked against this receptor, β-sitosterol ranked first with a docking score of −7.0, indicating the most favorable predicted binding among the candidates. β-Sitosterol is a plant sterol structurally related to cholesterol, abundant in many seeds, nuts, and plant oils, and previously studied for cholesterol-lowering and other effects. Its top ranking here positioned it as the primary candidate for the deeper computational analyses that followed.

Before committing to expensive simulation work, the team assessed the drug-like properties of β-sitosterol using QuickProp analysis, a rapid computational method for estimating absorption, distribution, metabolism, and excretion parameters. The results were mixed and, importantly, the authors were candid about the limitations. On the positive side, QuickProp predicted high membrane permeability, which is often desirable for oral absorption. However, the analysis also revealed high lipophilicity, extremely poor aqueous solubility, and multiple property alerts. These characteristics point to a practical problem: molecules that dissolve poorly in water may fail to reach meaningful concentrations in the bloodstream after oral administration, regardless of how well they permeate membranes once dissolved. The authors explicitly noted that dissolution and formulation limitations may restrict the compound’s actual oral exposure, a caution that tempers any simple translation of the docking results into expectations about therapeutic efficacy in patients or animals.

The centerpiece of the computational work was a 500-nanosecond molecular dynamics simulation of the β-sitosterol–3HA8 complex. Docking provides a static snapshot of a predicted binding mode, but proteins and ligands in solution are constantly in motion, and a docking pose that looks good on paper may fall apart within nanoseconds of realistic simulation. Molecular dynamics addresses this by simulating the physical movements of every atom in the system over time. The team subjected the complex to a half-microsecond simulation and then analyzed the trajectory with a battery of complementary metrics. Root mean square deviation (RMSD) tracks how far the protein and ligand drift from their starting positions; root mean square fluctuation (RMSF) measures flexibility residue by residue; protein–ligand contact analysis catalogues the specific interactions—hydrogen bonds, hydrophobic contacts, and others—that persist over the simulation; principal component analysis (PCA) identifies the dominant collective motions of the protein; the free energy landscape (FEL) maps the conformational states the complex explores; and the dynamic cross-correlation matrix (DCCM) reveals how motions in different parts of the protein are coordinated. According to the study, all of these analyses indicated stable binding and favorable conformational behavior for the β-sitosterol–3HA8 complex across the full simulation, lending credibility to the docking result.

In parallel, the researchers performed density functional theory (DFT) calculations, a quantum chemical method that describes the electronic structure of molecules. From these calculations they obtained a HOMO-LUMO energy gap of 6.90 electron volts for β-sitosterol. The HOMO-LUMO gap is the energy difference between the highest occupied and lowest unoccupied molecular orbitals, and a large gap generally signifies a chemically “hard” molecule—one that is less prone to donate or accept electrons readily and therefore less reactive in charge-transfer or redox chemistry. The authors interpreted the 6.90 eV gap as consistent with a chemically hard electronic structure and a comparatively low propensity for frontier-orbital excitation within the applied computational model. For a sterol that acts largely through hydrophobic and steric interactions with a protein binding site, such electronic inertness is not surprising, though the authors appropriately scoped the interpretation to the model they used.

Computational predictions, however encouraging, do not by themselves establish biological activity. The team therefore carried out two classical in vitro assays of anti-inflammatory potential. The first measured the inhibition of protein denaturation, a widely used surrogate assay based on the observation that many anti-inflammatory agents protect proteins from heat-induced or chemically induced denaturation, a process thought to contribute to inflammation by exposing new antigenic epitopes. The second was the human red blood cell (HRBC) membrane stabilization assay, which exploits the similarity between red blood cell membranes and lysosomal membranes; compounds that stabilize red blood cells against hemolysis under stress are presumed to have the capacity to stabilize lysosomal membranes and thereby limit the release of inflammatory mediators. In both assays, β-sitosterol-containing preparations from the study showed concentration-dependent effects. At the highest tested concentration of 300 micrograms per milliliter, inhibition of protein denaturation reached 76.32 ± 1.35 percent, and HRBC membrane stabilization reached 82.47 ± 1.42 percent. These are substantial effects in the context of such assays, and the concentration dependence supports a direct relationship between the amount of compound present and the protective effect observed.

Taken together, the study builds a layered argument for β-sitosterol as a contributor to the anti-inflammatory potential of I. carnea. The network pharmacology places it among compounds whose targets span the major inflammatory pathways; docking ranks it first against the chosen receptor; a long molecular dynamics simulation supports the physical stability of that interaction; DFT characterizes its electronic behavior; and the in vitro assays demonstrate genuine, dose-dependent biochemical effects on protein denaturation and membrane stability. The authors summarized the case as one of multi-target pathway modulation, stable receptor interaction, and membrane-protective effects, while explicitly stating that further experimental validation is required—a necessary caveat given the nature of the evidence.

That caveat deserves emphasis. The in vitro assays used here are screening-level tools: they measure general biophysical effects rather than the modulation of specific inflammatory signaling events in living cells or organisms. The study did not report enzyme inhibition assays against the identified targets such as TNF, IL6, or the MAP kinases, nor did it include cell-based assays of cytokine production or animal models of inflammation. The docking and simulation results are predictions about one receptor structure, and real biological activity would require confirming that β-sitosterol binds and modulates this and the other network targets in experimental systems. Moreover, the pharmacokinetic concerns raised by QuickProp—extremely poor aqueous solubility in particular—mean that even a genuinely active compound may struggle to achieve effective concentrations in vivo without advanced formulation strategies such as lipid-based delivery systems, which are already used for other lipophilic nutraceuticals.

There is also broader context worth noting. Ipomoea carnea Jacq., commonly known as bush morning glory, is a flowering shrub widespread in tropical and subtropical regions and used in folk medicine across its range, but it is also documented to contain toxic compounds such as swainsonine, and its safety profile is a matter of ongoing study. The present work examined individual phytoconstituents rather than the plant itself, which is the appropriate strategy for separating beneficial molecules from harmful ones. β-Sitosterol itself has an established safety record in the nutritional literature, where it is consumed as a cholesterol-lowering supplement, which may ease the path toward further development, although doses and contexts differ substantially between supplements and potential anti-inflammatory therapeutics.

The study’s chief contribution is methodological as much as substantive: it illustrates how a tiered pipeline—network pharmacology to define plausible targets, docking to prioritize candidates, property prediction to flag liabilities, molecular dynamics and quantum chemistry to stress-test the leading hit, and in vitro assays to confirm biochemical activity—can efficiently triage natural product constituents before more costly biological experimentation. For β-sitosterol from I. carnea, the next steps suggested by the evidence would include target-specific biochemical assays, cell-based models of inflammatory signaling, and pharmacokinetic studies addressing solubility and bioavailability. Until such work is done, the finding stands as a promising but preliminary indication that a familiar plant sterol may help explain the anti-inflammatory potential of a widely used medicinal shrub.